Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003). These data include 1,225 men whose cancer was detected during the 7-year trial--556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial end. Symptomatic BPH was assessed hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (International Prostate Symptom Score >14), or physician diagnosis, and analyses were completed by BPH status at baseline (prevalent) or BPH prior to cancer diagnosis or study end (prevalent plus incident). Controlled for age, race, and body mass index, neither prevalent (risk ratio = 1.03, 95% confidence interval: 0.92, 1.14) nor prevalent plus incident (risk ratio = 0.96, 95% confidence interval: 0.87, 1.06) symptomatic BPH was associated with prostate cancer risk. This lack of association was consistent across subgroups defined by type of BPH-defining event (treatment, symptoms, or physician diagnosis), prompt for prostate cancer diagnosis, and prostate cancer grade. This study provides the strongest evidence to date that BPH does not increase the risk of prostate cancer.

[1]  I. Thompson,et al.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2010, American journal of epidemiology.

[2]  I. Thompson,et al.  Alcohol consumption, finasteride, and prostate cancer risk , 2009, Cancer.

[3]  I. Thompson,et al.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[4]  J. Stanford,et al.  Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men , 2008, Cancer Causes & Control.

[5]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[6]  J. Oesterling,et al.  Interpreting results of prostate-specific antigen testing for early detection of prostate cancer , 1996, Journal of General Internal Medicine.

[7]  Donna Spiegelman,et al.  Easy SAS calculations for risk or prevalence ratios and differences. , 2005, American journal of epidemiology.

[8]  R. Hiatt,et al.  Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States) , 2005, Cancer Causes & Control.

[9]  R. Getzenberg,et al.  Fingerprinting the diseased prostate: Associations between BPH and prostate cancer , 2004, Journal of cellular biochemistry.

[10]  H. Adami,et al.  Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia , 2003, Cancer.

[11]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[12]  Xiaonan Xue,et al.  Estimating the relative risk in cohort studies and clinical trials of common outcomes. , 2003, American journal of epidemiology.

[13]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[14]  C. Foster,et al.  Pathology of benign prostatic hyperplasia , 2000, The Prostate. Supplement.

[15]  D. S. Coffey,et al.  New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. , 1999, Urology.

[16]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[17]  M. Barry,et al.  High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. , 1998, The American journal of medicine.

[18]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[19]  D. Ornstein,et al.  The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. , 1997, The Journal of urology.

[20]  A. Partin,et al.  Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. , 1996, The Journal of urology.

[21]  C. Lee,et al.  Role of androgen in prostate growth and regression: Stromal‐epithelial interaction , 1996, The Prostate. Supplement.

[22]  John T. Wei,et al.  The influence of prostate size on cancer detection. , 1995, Urology.

[23]  J. Oesterling,et al.  Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? , 1995, Urology.

[24]  A. Morrison,et al.  The relation of surgery for prostatic hypertrophy to carcinoma of the prostate. , 1993, American journal of epidemiology.

[25]  J. Oesterling,et al.  A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. , 1993, Archives of family medicine.

[26]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[27]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[28]  F. Schröder,et al.  Natural history of benign prostatic hyperplasia (BPH) , 1989, The Prostate. Supplement.

[29]  T. Stamey,et al.  Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.

[30]  E. Fraley,et al.  Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. , 1980, The Journal of urology.

[31]  B. Hølund.  Latent prostatic cancer in a consecutive autopsy series. , 1980, Scandinavian journal of urology and nephrology.

[32]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[33]  P. Greenwald,et al.  Cancer of the prostate among men with benign prostatic hyperplasia. , 1974, Journal of the National Cancer Institute.

[34]  A. Lilienfeld,et al.  Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. , 1974, Lancet.

[35]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[36]  R. D. Turner,et al.  The results of 1,694 consecutive simple perineal prostatectomies. , 1957, The Journal of urology.

[37]  S. Sommers.  Endocrine changes with prostatic carcinoma , 1957, Cancer.

[38]  M. Labess.  Occult carcinoma in clinically benign hypertrophy of the prostate; a pathological and clinical study. , 1952, The Journal of urology.